News

Blueprint Medicines Announces Next Step for Avaprinitib

Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST Blueprint Medicines announced today that the FDA and the EMA have [...]

By |2019-08-07T13:24:21-04:00August 7th, 2019|Drug Treatment, News|

Creating Your Personal Cancer Survival Plan

This Personal Cancer Survival Plan is based upon practical observations gained from my experience [Norman Scherzer] of keeping my wife alive with a rare cancer called GIST (Gastrointestinal Stromal Tumor) for 22 years after she was given six months to live, and hundreds of patient medical histories and stories that come across The Life Raft Group forums and medical databases.

By |2019-08-29T11:51:08-04:00July 10th, 2019|GIST Education, GIST Survival Plan, News, Patient Support, Video|

GIST Day of Learning – GDOL Portland

The Life Raft Group held a GIST Day of Learning (GDOL) in Portland, at Oregon Health & Science University (OHSU), on June 22nd, 2019. Top GIST specialists presented the latest on research and treatment options and provided a comprehensive review of the science behind GIST.

By |2019-09-23T15:59:29-04:00July 9th, 2019|GDOL, GIST Education, News|
Go to Top